SCHEMBL857092

SCHEMBL857092

Cc1ncc(S(=O)(=O)N(C)C)c(Cl)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.41
TSHR P16473 2/20 0.39
MAPT P10636 1/20 0.39
ALDH1A1 P00352 7/20 0.39
GLA P06280 1/20 0.38
HTT P42858 1/20 0.35
ALOX5AP P20292 2/20 0.35
FEN1 P39748 2/20 0.35
LMNA P02545 1/20 0.35
THRB P10828 1/20 0.35
KDM4E B2RXH2 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
GSTO1 P78417 2/20 0.33
POLB P06746 2/20 0.33
MEN1 O00255 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
KCNJ6 P48051 2/20 0.33
KCNJ5 P48544 2/20 0.33
KCNJ3 P48549 2/20 0.33
NPC1 O15118 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9547067 0.79 KMT2A (0.44) KMT2AMAPTALDH1A1HTTALOX5AP
SCHEMBL27267594 0.78 KMT2A (0.43) KMT2AMAPTALDH1A1HTTLMNA
SCHEMBL26608096 0.71 TSHR (0.45) KMT2ATSHRMAPTALDH1A1GLA
SCHEMBL1458926 0.71 ALDH1A1 (0.42) TSHRMAPTALDH1A1GLALMNA
SCHEMBL26607978 0.70 ALDH1A1 (0.41) KMT2ATSHRMAPTALDH1A1GLA
SCHEMBL2203744 0.68 GRM5 (0.44) KMT2AALDH1A1HTTALOX5APFEN1
SCHEMBL29452131 0.68 TSHR (0.45) KMT2ATSHRMAPTALDH1A1GLA
SCHEMBL31296076 0.68 TSHR (0.49) KMT2ATSHRMAPTALDH1A1GLA
SCHEMBL19225455 0.67 AXL (0.45) ALOX5APFEN1
SCHEMBL5860975 0.67 KMT2A (0.53) KMT2AMAPTALDH1A1HTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-03-20 US disclosed
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US disclosed
EP-2640366-A2 BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE Exelixis, Inc. (US) 2013-09-25 EP disclosed
WO-2012068096-A2 BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE EXELIXIS, INC. (US) 2012-05-24 WO disclosed
EP-2432779-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES Exelixis, Inc. (US) 2012-03-28 EP disclosed
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2010-11-25 US disclosed
WO-2010135524-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES EXELIXIS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA KMT2A 2645/4885TSHR 3801/4885MAPT 1278/4885
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA KMT2A 3064/4885TSHR 3795/4885MAPT 1639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.